The primary positive trial Reis has major anomolies Kelleni. Results from NCT04967430 have not been reported and contact information was deleted in the registry.
Submit updates/corrections .
Sep 24 |
Peginterferon Lambda for COVID-19: real-time meta analysis of 4 studies | |
| Meta analysis using the most serious outcome reported shows 7% [-138‑63%] lower risk, without reaching statistical significance. Early treatment is more effective than late treatment. Currently all studies are RCTs. • 2 studi.. | ||
Mar 16 |
, M., Center for Open Science, doi:10.31219/osf.io/5xd6q | Peg-interferon Lambda Single Dose Treatment for COVID-19: A Call to Avoid another Hydroxychloroquine Fiasco |
| Review of critical issues with [Reis]. Author notes that NEJM declined to publish these issues without comment. | ||
Feb 24 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828 | Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial |
| 200% higher ICU admission (p=1), 25% longer hospitalization (p=0.59), and 12% improved viral clearance (p=1). Very small RCT with 14 hospitalized patients in the USA showing no significant differences with peginterferon lambda. Viral load was improved, however 86% of treatment versus 14% of control patients received remdesivir, and the median bas.. | ||
Feb 9 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2209760 | Early Treatment with Pegylated Interferon Lambda for Covid-19 |
| 27% lower mortality (p=0.76), 42% lower hospitalization (p=0.04), and 51% fewer combined hospitalization/ER visits (p=0.003). High-risk outpatient RCT with 931 peginterferon lambda patients and 1,018 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection. There were 85/931 and 286/1018 patients for w.. | ||
Mar 30 2021 |
et al., Nature Communications, doi:10.1038/s41467-021-22177-1 | Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial |
| no change in hospitalization (p=1), 6% worse recovery (p=0.76), and 14% worse viral clearance (p=0.91). RCT 120 outpatients with mild/moderate COVID-19, showing no significant differences with peginterferon lambda-1a treatment. 180μg subcutaneous peginterferon lambda-1a. NCT04331899. | ||
Nov 12 2020 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (date from preprint) | Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial |
| 75% lower progression (p=0.35) and 66% improved viral clearance (p=0.03). Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.